...
eras-img

Erasca Inc, Common Stock

ERAS

NSQ

$2.49

-$0.14

(-5.32%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$740.74M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.80M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.16
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.64 L
$3.45 H
$2.49

About Erasca Inc, Common Stock

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameERASSectorS&P500
1-Week Return-10.43%-2.06%-0.55%
1-Month Return-8.79%-1.92%2.72%
3-Month Return-13.84%-10.4%7.66%
6-Month Return22.06%-4.6%10.15%
1-Year Return35.33%4.06%27.53%
3-Year Return-81.93%1.94%32.31%
5-Year Return-85.71%36.48%89.2%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue310.00K540.00K829.00K2.64M3.73M[{"date":"2019-12-31","value":8.31,"profit":true},{"date":"2020-12-31","value":14.47,"profit":true},{"date":"2021-12-31","value":22.21,"profit":true},{"date":"2022-12-31","value":70.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(310.00K)(540.00K)(829.00K)(2.64M)(3.73M)[{"date":"2019-12-31","value":-31000000,"profit":false},{"date":"2020-12-31","value":-54000000,"profit":false},{"date":"2021-12-31","value":-82900000,"profit":false},{"date":"2022-12-31","value":-264100000,"profit":false},{"date":"2023-12-31","value":-373200000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses13.29M37.51M96.54M145.45M141.53M[{"date":"2019-12-31","value":9.14,"profit":true},{"date":"2020-12-31","value":25.79,"profit":true},{"date":"2021-12-31","value":66.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.3,"profit":true}]
Operating Income(13.29M)34.24M(124.88M)(247.45M)(141.53M)[{"date":"2019-12-31","value":-38.83,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-364.75,"profit":false},{"date":"2022-12-31","value":-722.73,"profit":false},{"date":"2023-12-31","value":-413.36,"profit":false}]
Total Non-Operating Income/Expense2.56M7.93M2.31M9.55M31.84M[{"date":"2019-12-31","value":8.03,"profit":true},{"date":"2020-12-31","value":24.9,"profit":true},{"date":"2021-12-31","value":7.25,"profit":true},{"date":"2022-12-31","value":29.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(12.04M)(101.66M)(122.76M)(242.81M)(125.04M)[{"date":"2019-12-31","value":-1204000000,"profit":false},{"date":"2020-12-31","value":-10166000000,"profit":false},{"date":"2021-12-31","value":-12276400000,"profit":false},{"date":"2022-12-31","value":-24280500000,"profit":false},{"date":"2023-12-31","value":-12504200000,"profit":false}]
Income Taxes(1.30M)71.41M27.33M(4.64M)-[{"date":"2019-12-31","value":-1.82,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":38.27,"profit":true},{"date":"2022-12-31","value":-6.5,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(10.74M)(173.07M)(150.09M)(238.16M)-[{"date":"2019-12-31","value":-1073700000,"profit":false},{"date":"2020-12-31","value":-17306900000,"profit":false},{"date":"2021-12-31","value":-15009000000,"profit":false},{"date":"2022-12-31","value":-23816000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(12.04M)(101.66M)(122.76M)(242.81M)(230.59M)[{"date":"2019-12-31","value":-1204000000,"profit":false},{"date":"2020-12-31","value":-10166000000,"profit":false},{"date":"2021-12-31","value":-12276400000,"profit":false},{"date":"2022-12-31","value":-24280500000,"profit":false},{"date":"2023-12-31","value":-23059100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(10.74M)(173.07M)(150.09M)(238.16M)(125.04M)[{"date":"2019-12-31","value":-1073700000,"profit":false},{"date":"2020-12-31","value":-17306900000,"profit":false},{"date":"2021-12-31","value":-15009000000,"profit":false},{"date":"2022-12-31","value":-23816000000,"profit":false},{"date":"2023-12-31","value":-12504200000,"profit":false}]
EPS (Diluted)(0.96)(0.68)(2.67)(1.96)(0.83)[{"date":"2019-12-31","value":-95.55,"profit":false},{"date":"2020-12-31","value":-67.52,"profit":false},{"date":"2021-12-31","value":-266.5,"profit":false},{"date":"2022-12-31","value":-196,"profit":false},{"date":"2023-12-31","value":-83,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ERAS
Cash Ratio 10.62
Current Ratio 11.00

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ERAS
ROA (LTM) -19.14%
ROE (LTM) -38.90%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ERAS
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ERAS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.65
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Erasca Inc share price today?

Erasca Inc (ERAS) share price today is $2.49

Can Indians buy Erasca Inc shares?

Yes, Indians can buy shares of Erasca Inc (ERAS) on Vested. To buy Erasca Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ERAS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Erasca Inc be purchased?

Yes, you can purchase fractional shares of Erasca Inc (ERAS) via the Vested app. You can start investing in Erasca Inc (ERAS) with a minimum investment of $1.

How to invest in Erasca Inc shares from India?

You can invest in shares of Erasca Inc (ERAS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ERAS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Erasca Inc shares
What is Erasca Inc 52-week high and low stock price?

The 52-week high price of Erasca Inc (ERAS) is $3.45. The 52-week low price of Erasca Inc (ERAS) is $1.64.

What is Erasca Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Erasca Inc (ERAS) is

What is Erasca Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Erasca Inc (ERAS) is 1.65

What is Erasca Inc dividend yield?

The dividend yield of Erasca Inc (ERAS) is 0.00%

What is the Market Cap of Erasca Inc?

The market capitalization of Erasca Inc (ERAS) is $740.74M

What is Erasca Inc’s stock symbol?

The stock symbol (or ticker) of Erasca Inc is ERAS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top